102ND GENERAL ASSEMBLY
State of Illinois
2021 and 2022
HB3048
 
Introduced 2/19/2021, by Rep. Adam Niemerg
 
SYNOPSIS AS INTRODUCED:
 

 
20 ILCS 2310/2310-578 new

     Amends the Department of Public Health Powers and Duties Law of the Civil Administrative Code of Illinois. Requires the Department of Public Health to create and maintain a list of each immunizing agent derived from aborted fetal tissue and any alternative immunizing agents. Provides that the Department shall ensure that, before administering an immunizing agent derived from aborted fetal tissue to an individual, a health care provider shall provide to the individual or, if the individual is a child, to the parent, guardian, or person in loco parentis of the child: (1) notification that the immunizing agent was derived from aborted fetal tissue; (2) if an immunizing agent that is not an immunizing agent derived from aborted fetal tissue is available as an alternative to an immunizing agent derived from aborted fetal tissue, an offer of the alternative; and (3) notification of the option to decline the receipt of the immunizing agent. Effective immediately.
  


LRB102 13915 CPF 19266 b

FISCAL NOTE ACT MAY APPLY
 
 
A BILL FOR
 

  
HB3048LRB102 13915 CPF 19266 b


  
1    AN ACT concerning health.
  
 
2    Be it enacted by the People of the State of Illinois,
 
3represented in the General Assembly:
  
 
 
4    Section 5. The Department of Public Health Powers and 
5Duties Law of the
Civil Administrative Code of Illinois is 
6amended  by adding Section 2310-578 as follows:
 
7    (20 ILCS 2310/2310-578 new)
8    Sec. 2310-578. Immunizing agents derived from aborted 
9fetal tissue.
10    (a) As used in this Section: 
11    "Health care provider" means any physician, advanced 
12practice registered nurse, physician assistant, hospital 
13facility, or other person that is licensed or otherwise 
14authorized to deliver health care services.
15    "Immunizing agent derived from aborted fetal tissue" means

16an immunizing agent that is manufactured using a human fetal 
17or
embryonic cell line, protein, deoxyribonucleic acid, 
18recombinant
deoxyribonucleic acid, monoclonal antibody, or any 
19other component
derived from an elective abortion or using a 
20cell line derived from
the tissue of a fetus that was 
21electively aborted.
22    (b) The Department shall create and maintain a
list of 
23each immunizing agent derived from aborted fetal tissue. If
an 
 
 
HB3048- 2 -LRB102 13915 CPF 19266 b

1immunizing agent that is not an immunizing agent derived from

2aborted fetal tissue is available as an alternative to an

3immunizing agent derived from aborted fetal tissue, the 
4Department
shall include the alternative on the list. The 
5Department shall
update the list annually and make the list 
6available to the public
on the Department's website. 
7    (c) The Department shall ensure that, beginning January 1, 
82022, before administering an immunizing agent derived from 
9aborted fetal tissue to an individual, a health care provider 
10shall notify the individual or, if the individual is a child, 
11the parent, guardian, or person in loco parentis of the child 
12that the immunizing agent was derived from aborted fetal 
13tissue. If an immunizing agent that is not an immunizing agent 
14derived from aborted fetal tissue is available as an 
15alternative to an immunizing agent derived from aborted fetal 
16tissue, the health care provider shall offer the alternative 
17to the individual or, if the individual is a child, to the 
18parent, guardian, or person in loco parentis of the child. A 
19health care provider shall also notify the individual or, if 
20the individual is a child, the parent, guardian, or person in 
21loco parentis of the child of the option to decline the receipt 
22of the immunizing agent. 
 
 
23    Section 99. Effective date. This Act takes effect upon 
24becoming law.